Article
BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy.
Pharmacological research - 1 Aug 2022
Porcelli Letizia, Di Fonte Roberta, Pierri Ciro L, Fucci Livia, Saponaro Concetta, Armenio Andrea, Serratì Simona, Strippoli Sabino, Fasano Rossella, Volpicella Mariateresa, Daprile Rossana, Tommasi Stefania, Ressa Cosmo M, Guida Michele, Azzariti Amalia
Abstract excerpt
The V600E mutation in BRAF is associated with increased phosphorylation of Erk1/2 and high sensitivity to BRAFi/MEKi combination in metastatic melanoma. In very few patients, a tandem mutation in BRAF, V600 and K601, causes a different response to BRAFi/MEKi combination. BRAFV600E;K601Q patient-derived organoids (PDOs) were generated to investigate targeted therapy efficacy and docking analysis was used to assess...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.